Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population

Cancer Detection and Prevention

Volumn 30, Issue 3, 2006, Pages 262-268

  Okugi, Hironobu ^a   Nakazato, Haruki ^a   Matsui, Hiroshi ^a   Ohtake, Nobuaki ^a   Nakata, Seiji ^a   Suzuki, Kazuhiro ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

5 Reductase; AR CAG repeat; CYP17; Family history; Genetic polymorphism; Genetic susceptibility; Genomic DNA; Genotyping; Prostate cancer; PSA promoter; Risk factors; Single nucleotide polymorphisms; SRD5A2; UGT2B15

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CYTOCHROME P450 17; GLUCURONOSYLTRANSFERASE; STEROID 5ALPHA REDUCTASE;

ADULT; AGED; ALLELE; ANDROGEN METABOLISM; ARTICLE; CANCER RISK; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; ETHNIC GROUP; FAMILY HISTORY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANDROGENS; CASE-CONTROL STUDIES; GLUCURONOSYLTRANSFERASE; HUMANS; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; SIGNAL TRANSDUCTION; STEROID 17-ALPHA-HYDROXYLASE;

EID: 33746718045     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2006.04.004     Document Type: Article

References (51)

1. Parker S.L., Tong T., Bolden S., and Wingo P.A. Cancer statistics. CA Cancer J Clin 47 (1997) 5-27
2. Nakata S., Sato J., Ohtake N., and Yamanaka H. Regional and chronological differences of urogenital cancer death in Japan. Int J Urol 87 (1996) 1313-1320
3. Ross R.K., Pike M.C., Gerhard A.C., Reichardt J.V., Yu M.C., Feigelson H., et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58 (1998) 4497-4504
4. Warterman M.R., and Keeney D.S. Genes involved in androgen biosynthesis and the male phenotype. Horm Res 38 (1992) 217-221
5. Carey A.H., Waterworth D., Patel K., White D., Little J., Novelli P., et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 3 (1994) 1873-1876
6. Makridakis N.M., Ross R.K., Pike M.C., Crocitto L.E., Kolonel L.N., Pearce C.L., et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354 (1999) 975-978
7. Makridakis N., Ross R.K., Pike M.C., Chang L., Stanczyk F.Z., Kolonel L.N., et al. A prevalence missense substitution that modulates activities of prostatic steroid 5α-reductase. Cancer Res 57 (1997) 1020-1022
8. Li Z., Habuchi T., Mitsumori K., Kamoto T., Kinoshitu H., Segawa T., et al. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J Urol 169 (2003) 2378-2381
9. Mackenzie P.I., Mojarrabi B., Meech R., and Hansen A. Steroid UDP glucuronosyltransferase: characterization and regulation. J Endocrinol 150 (1996) S79-S86
10. Belanger G., Beaulieu M., Marcotte B., Levesque E., Guillemette C., Hum D.W., et al. Expression of transcripts encoding steroid UDP-glucuronosyltransferases in human prostate hyperplastic tissue and the LNCaP cell line. Mol Cell Endocrinol 113 (1995) 165-173
11. Tut T.G., Ghadessy F.J., Trifiro M.A., Pinsky L., and Young E.L. Long polyglutamine tracts in the androgen receptor are associated with reduced transactivation, impaired sperm production and male infertility. J Clin Endocrinol Metab 82 (1997) 3777-3782
12. Grieson A.J., Mootoosamy R.C., and Miller C.C.J. Polyglutamine repeat length influences human androgen receptor/c-Jun mediated transcription. Neurosci Lett 177 (1999) 9-12
13. Irvine R.A., Yu M.C., Ross K.R., and Coetzee G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55 (1995) 1935-1940
14. Giovannucci E., Stampfer M.J., Krithivas K., Brown M., Brufsky A., Talcott J., et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94 (1997) 3320-3323
15. Ingles S.A., Ross R.K., Yu M.C., Irvine R.A., La Pera G., Haile R.W., et al. Association of prostate cancer risk with genetic polymorphisms in Vitamin D receptor and androgen receptor. J Natl Cancer Inst 89 (1997) 166-170
16. Stanford J.L., Just J.J., Gibbs M., Wcklund K.G., Neal C.L., Blumenstein B.A., et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 57 (1997) 1194-1198
17. Bratt O., Borg A., Kristoffersson U., Lundgren R., Zhang Q.X., and Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 81 (1999) 672-677
18. Kennedy-Smith A.G., McKenzie J.L., Owen M.C., Davidson P.J., Vuckovic S., and Hart D.N. Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer. J Urol 168 (2002) 741-747
19. Jia L., Kim J., Shen H., Clark P.E., Tilley W.D., and Coetzee G.A. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res 1 (2003) 385-392
20. Xue W., Irvine R.A., Yu M.C., Ross R.K., Coetzee G.A., and Ingles S.A. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 60 (2000) 839-841
21. Yang Q., Shan L., Segawa N., Nakamura M., Nakamura Y., Mori I., et al. Novel polymorphisms in prostate specific antigen gene and its association with prostate cancer. Anticancer Res 21 (2001) 197-200
22. Ohtake N., Hatori M., Yamanaka H., Nakata S., Sada M., and Tsuji T. Familial prostate cancer in Japan. Int J Urol 5 (1998) 138-145
23. Ohtake N., Nakata S., Fukabori Y., Suzuki K., and Yamanaka H. Update of familial prostate cancer in Japan. Nihon Rinsho 60 (2002) 469-473 [in Japanese]
24. Bratt O. Hereditary prostate cancer: clinical aspect. J Urol 168 (2002) 906-913
25. Smith J.R., Freije D., Carpten J.D., et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274 (1996) 1371-1374
26. Xu J., Meyers D., Freije D., Isaacs S., Wiley K., Nusskern D., et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 20 (1998) 175-179
27. Tavtigian S.V., Simard J., Teng D.H., Abtin V., Baumgard M., Beck A., et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 27 (2001) 172-180
28. Carpten J., Nupponen N., Isaacs S., Sood R., Robbins C., Xu J., et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30 (2002) 181-184
29. Suzuki K., Ohtake N., Nakata S., Takei T., Matsui H., Ono Y., et al. Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population. Anticancer Res 22 (2002) 3507-3512
30. Nakazato H., Suzuki K., Matsui H., Ohtake N., Nakata S., and Yamanaka H. Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer 89 (2003) 691-696
31. Suzuki K., Matsui H., Ohtake N., Nakata S., Takei T., Okugi H., et al. Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population. Int J Urol 10 (2003) 261-266
32. Suzuki K., Matsui H., Nakazato H., Koike H., Okugi H., Hasumi M., et al. Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: a case-control study. Cancer Lett 195 (2003) 177-183
33. Nakazato H., Suzuki K., Matsui M., Koike H., Okugi H., Ohtake N., et al. Association of genetic polymorphisms of glutathione S-transferase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population. Anticancer Res 23 (2003) 2897-2902
34. Suzuki K., Matsui H., Ohtake N., Nakata S., Takei T., Okugi H., et al. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci 10 (2003) 430-435
35. Carter B.S., Bova G.S., Beaty T.H., Steinberg G.D., Childs B., Isaacs W.B., et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150 (1993) 797-802
36. Yoshida K.I., Yano M., Chiba K., Honda M., and Kitahara S. CAG repeat length in the androgen receptor gene is enhanced in patients with idiopathic azoospermia. Urology 54 (1999) 1078-1081
37. Suzuki K., Fukabori Y., Nakazato H., Hasumi M., Matsui H., Ito K., et al. Novel amino acid substitutional mutation, tyrosine-739-aspartic acid, in the androgen receptor gene in complete androgen insensitivity syndrome. Int J Androl 24 (2001) 183-188
38. MacLeod S.L., Nowell S., Plaxco J., and Lnag N.P. An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer. Ann Surg Oncol 7 (2000) 777-782
39. Gsur A., Bernhofer G., Hinteregger S., Haidinger G., Schatzl G., Madersbacher S., et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 87 (2000) 434-437
40. Yamada Y., Watanabe M., Murata M., Yamanaka M., Kubota Y., Ito H., et al. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5α-reductase type II (SRD 5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 92 (2001) 638-689
41. Levesque E., Beaulieu M., Guillemette C., Hum D.W., and Belanger A. Effect of fibroblastic growth factors (FGF) on steroid UDP-glucuronosyltransferase expression and activity in the LNCaP cell line. J Steroid Biochem Mol Biol 64 (1998) 43-48
42. Kanay J., Takahashi M., Koh E., and Namiki M. Androgen-independent growth in LNCaP cell lines and steroid uridine-diphosphate-glucuronosyltransferase expression. Asian J Androl 5 (2003) 9-13
43. Levesque E., Beaulieu M., Green M.D., Tephly T.R., Belanger A., and Hum D.W. Isolation and characterization of UGT2B15 (Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 7 (1997) 317-325
44. Ross R., Bernstein L., Judd H., Hanisch R., Pike M., and Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 76 (1986) 45-48
45. Gann P.H., Hennekens C.H., Ma J., Longcope C., and Stampfer M.J. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88 (1996) 1118-1126
46. Lunn R.M., Bell D.A., Mohler J.L., and Taylor J.A. Prostate cancer risk and polymorphims in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 20 (1999) 1727-1731
47. Wadelius M., Andersson S.O., Johansson J.E., Wadelius C., and Rane A. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 9 (1999) 635-639
48. Habuchi T., Liqing Z., Suzuki T., Sasaki R., Tsuchiya N., Tachiki H., et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 60 (2000) 5710-5713
49. Modugno F., Weissfeld J.L., Trump D.L., Zmuda J.M., Shea P., Cauley J.A., et al. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 7 (2001) 3092-3096
50. Shibata A., Stamey T.A., McNeal J.E., Cheng I., and Peehl D.M. Genetic polymorphisms in the androgen receptor and type II 5α-reductase genes in prostate enlargement. J Urol 166 (2001) 1560-1564
51. Azzouzi A.R., Cochand-Priollet B., Mangin P., Fournier G., Berthon P., Latil A., et al. Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate. Eur J Endocrinol 147 (2002) 479-484